Abstract: The present invention describes a reverse genetic system for Phlebovirus such as Rift Valley fever virus. This system comprised of RNA expression plasmids and protein expression plasmids. Additionally, the present invention also discloses the modification of this system to generate a recombinant virus that expresses a non-viral foreign gene. Furthermore, the present invention discloses the use of this system in the development of anti-Rift Valley fever virus vaccines, screening of antivirals testing for anti RVF immune response and developing marker vaccines for Rift Valley fever virus. We also claim the utility of this approach to other phleboviruses.

Abstract: An aluminum alloy extruded product includes an aluminum alloy including 6.0 to 7.2 mass % of Zn, 1.0 to 1.6 mass % of Mg, 0.1 to 0.4 mass % of Cu, at least one component selected from the group consisting of Mn, Cr, and Zr in a respective amount of 0.25 mass % or less and a total amount of 0.15 to 0.25 mass %, 0.20 mass % or less of Fe, and 0.10 mass % or less of Si, with the balance substantially being aluminum, the aluminum alloy extruded product having a hollow cross-sectional shape, a recrystallization rate of 20% or less of a cross-sectional area of the extruded product, and a 0.2% proof stress of 370 to 450 MPa.

Abstract: An impact absorbing material formed by: casting an aluminum alloy into a billet, the aluminum alloy including 5.6 to 6.6 wt % of zinc, 0.75 to 1.10 wt % of magnesium, 0.10 to 0.25 wt % of copper, 0.05 to 0.20 wt % of manganese, 0.03 to 0.15 wt % of chromium, 0.10 to 0.25 wt % of zirconium, 0.02 to 0.10 wt % of silicon, 0.05 to 0.17 wt % of iron, and the balance being aluminum and unavoidable impurities; extruding the billet to obtain an extruded shape having a hollow cross-section; and subjecting the extruded shape to artificial aging so that 0.2% proof stress is in a range of 340 to 385 MPa.

Abstract: A door impact beam for a vehicle which includes a flange for receiving a load, a reinforcement body having approximately U shape in cross section and provided in one piece with the flange, a pair of separated side portions for connecting the reinforcement body to the flange, a bottom portion connected to the side portions via each curved portion, and the side portions having a configuration extended in an outward width direction while extended to the bottom portion direction.

Abstract: The present invention shows that expressed coronavirus envelope protein M specifically interacted with co-expressed non-coronavirus RNA transcripts containing the short viral packaging signal in the absence of coronavirus N protein. Furthermore, this M protein-packaging signal interaction led to specific packaging of the packaging-signal-containing RNA transcripts into coronavirus-like particles in the absence of N protein. These findings highlight a novel RNA packaging mechanism for an enveloped virus, and a novel coronavirus-based expression system can be developed based on the data presented herein.

Abstract: The object of the present invention is to stabilize bioactivation of iron salt. Said object is attained by adding a magnesium salt to said iron salt. Said iron salt stabilized by said magnesium salt is useful as medicine to treat incurable diseases such as diabetes and growth promoting agent of animals and plants.

Abstract: The object of the present invention is to improve the efficiency of combustion of fuel and to reduce toxic components contained in the combustion gas.

Abstract: A door impact beam for a vehicle which includes a flange for receiving a load, a reinforcement body having approximately U shape in cross section and provided in one piece with the flange, a pair of separated side portions for connecting the reinforcement body to the flange, a bottom portion connected to the side portions via each curved portion, and the side portions having a configuration extended in an outward width direction while extended to the bottom portion direction.

Abstract: Autoimmune diseases, cell adhesion inhibition and immunomodulation are treated or effected by a method, comprising, treating a patient with a therapeutically effective amount of a 4H-1-benzopyran-4-one compound represented by the following formula or a salt thereof: ##STR1## wherein R.sup.1 is an unsubstituted or halogen-substituted alkyl, alkenyl or aryl group; R.sup.2 is a hydrogen atom or an alkyl or acyl group; R.sup.3 is a hydrogen or halogen atom or a cyano, azido, carboxyl, hydroxyl, formyl or alkoxycarbonyl group or a substituted or unsubstituted alkyl, alkoxy, phenoxy, cycloalkyl, carbamoyl, amino or phenyl group; R.sup.4 is a hydrogen or halogen atom, a nitro, cyano, carboxyl, acyl, hydroxyl or alkoxycarbonyl group, or a substituted or unsubstituted alkyl, alkoxy, alkylthio, phenylthio, alkynyl, alkenyl, sulfamoyl, alkanesulfonyl, alkanesulfonyl, amidino, phenyl or heterocyclic group or a group of the formula ##STR2## where R.sup.